Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
| Autor: | Sabina Sandigursky, Daniel Chang Cho, Salman Rafi Punekar, Rochelle Castillo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Exacerbation Immunology Dermatomyositis Autoimmune Diseases Immunomodulating Agents Immune system Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Immunology and Allergy Adverse effect Carcinoma Renal Cell Immune Checkpoint Inhibitors Myositis Pharmacology biology business.industry Immunoglobulins Intravenous Cancer Middle Aged medicine.disease Kidney Neoplasms Discontinuation biology.protein Antibody business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Journal of Immunotherapy. 44:335-337 |
| ISSN: | 1524-9557 |
| DOI: | 10.1097/cji.0000000000000380 |
| Popis: | Immune checkpoint inhibitors (ICIs) are a class of medications targeting mostly the PD-1/PD-L1 and CTLA-4 immune pathways in the treatment of many cancers. Despite the encouraging success of ICIs, they are associated with immune-related adverse events as well as exacerbation of underlying autoimmune conditions. The treatment of these conditions often involves discontinuation of ICI in addition to the utilization of immunomodulatory agents. In this report, we discuss a case in which a patient with metastatic renal cell carcinoma experienced exacerbation of underlying paraneoplastic dermatomyositis after treatment with ICI. He was successfully continued on ICI with the use of intravenous immunoglobulin. The patient experienced adequate control of his myositis but also experienced deepening of his antitumor response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|